These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21226613)

  • 1. Therapeutics development for cystic fibrosis: a successful model for a multisystem genetic disease.
    Ashlock MA; Olson ER
    Annu Rev Med; 2011; 62():107-25. PubMed ID: 21226613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.
    Becq F
    Drugs; 2010 Feb; 70(3):241-59. PubMed ID: 20166764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress towards next-generation therapeutics for cystic fibrosis.
    O'Neil DA; Fraser-Pitt D
    Future Med Chem; 2014 Jun; 6(9):1067-79. PubMed ID: 25068988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology and management of pulmonary infections in cystic fibrosis.
    Gibson RL; Burns JL; Ramsey BW
    Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
    Birault V; Solari R; Hanrahan J; Thomas DY
    Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis.
    Amaral MD; Kunzelmann K
    Trends Pharmacol Sci; 2007 Jul; 28(7):334-41. PubMed ID: 17573123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome.
    Ren CL; Desai H; Platt M; Dixon M
    Pediatr Pulmonol; 2011 Nov; 46(11):1079-84. PubMed ID: 21538969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial concordance of phenotype and microbial variation among siblings with CF.
    Picard E; Aviram M; Yahav Y; Rivlin J; Blau H; Bentur L; Avital A; Villa Y; Schwartz S; Kerem B; Kerem E
    Pediatr Pulmonol; 2004 Oct; 38(4):292-7. PubMed ID: 15334505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs for cystic fibrosis.
    Wilschanski M; Kerem E
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1285-92. PubMed ID: 21745147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological therapy for cystic fibrosis: from bench to bedside.
    Becq F; Mall MA; Sheppard DN; Conese M; Zegarra-Moran O
    J Cyst Fibros; 2011 Jun; 10 Suppl 2():S129-45. PubMed ID: 21658632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
    Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
    Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary infection in mild variant cystic fibrosis: implications for care.
    Lording A; McGaw J; Dalton A; Beal G; Everard M; Taylor CJ
    J Cyst Fibros; 2006 May; 5(2):101-4. PubMed ID: 16426904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bringing new treatments to the bedside in cystic fibrosis.
    Brennan AL; Geddes DM
    Pediatr Pulmonol; 2004 Feb; 37(2):87-98. PubMed ID: 14730652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the diagnosis and treatment of cystic fibrosis.
    Martiniano SL; Hoppe JE; Sagel SD; Zemanick ET
    Adv Pediatr; 2014 Aug; 61(1):225-43. PubMed ID: 25037130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
    Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
    Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for cystic fibrosis.
    Amin R; Ratjen F
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):143-55. PubMed ID: 24479826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy.
    Lubamba B; Dhooghe B; Noel S; Leal T
    Clin Biochem; 2012 Oct; 45(15):1132-44. PubMed ID: 22698459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis.
    Dorfman R; Taylor C; Lin F; Sun L; Sandford A; Paré P; Berthiaume Y; Corey M; Durie P; Zielenski J;
    Pediatr Pulmonol; 2011 Apr; 46(4):385-92. PubMed ID: 20967843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cystic fibrosis transmembrane conductance regulator (CFTR) gene: mutations and clinical phenotypes].
    Schwartz M
    Ugeskr Laeger; 2003 Feb; 165(9):912-6. PubMed ID: 12661515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis.
    Guilbault C; De Sanctis JB; Wojewodka G; Saeed Z; Lachance C; Skinner TA; Vilela RM; Kubow S; Lands LC; Hajduch M; Matouk E; Radzioch D
    Am J Respir Cell Mol Biol; 2008 Jan; 38(1):47-56. PubMed ID: 17656682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.